(Q38235934)

31 August 2017

Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate (English)

1 reference

31 August 2017

Patricia A Corrigan

1

1 reference

31 August 2017

Teresa A Cicci

series ordinal

2

1 reference

31 August 2017

Jessica Johnston Auten

series ordinal

3

1 reference

31 August 2017

Denise K Lowe

series ordinal

4

1 reference

31 August 2017

language of work or name

English

0 references

publication date

31 July 2014

1 reference

Annals of Pharmacotherapy

31 August 2017

1 reference

31 August 2017

48

1 reference

31 August 2017

11

1 reference

31 August 2017

1484-1493

1 reference

31 August 2017

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

Antibody-drug conjugate (ADC) clinical pipeline: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545354

21 January 2018

Identifiers

DOI

10.1177/1060028014545354

1 reference

31 August 2017

1 reference